[This Week's IPO] August Second Week Demand Forecast and Subscription Schedule

In the second week of this month (August), Icecream Media will conduct a demand forecast targeting institutional investors. Euracle, Nextbiomedical, Jeonjin Construction Robot, K3I, and TDS Pharm are preparing for general subscription.

◆Icecream Media= Established in 2002, Icecream Media is Korea's first digital education platform company. Unlike other education companies, it has focused on the public education market rather than the private education market to grow. It exclusively owns approximately 6.5 million digital multimedia educational content archives called ‘EduBank AI’ in Korea and provides over 160 digital teaching tools and software services.

It plans to raise a total of 2.46 million shares entirely through new shares. The desired public offering price range per share is KRW 32,000 to KRW 40,200. The public offering price will be finalized through demand forecasting over five business days from the 9th to the 16th, and general subscription will be conducted on the 21st and 22nd. It is scheduled to be listed on the KOSDAQ market at the end of August, with Samsung Securities as the lead underwriter.

◆Euracle= The desired public offering price band per share is KRW 18,000 to KRW 21,000. Demand forecasting targeting institutional investors was conducted until the 2nd, and general subscription will be accepted on the 6th and 7th before listing. Kiwoom Securities is the lead underwriter.

Founded in 2001, Euracle has successfully completed over 1,000 customer projects in the mobile platform software market. It provides optimal software and services for mobile environments, including app development, operation, and maintenance for mobile businesses, and especially leads mobile standardization for large corporate groups.

◆Nextbiomedical= The planned public offering price is KRW 24,000 to KRW 29,000, with an expected offering amount of KRW 24 billion to KRW 29 billion. Demand forecasting was conducted until the 2nd, and after subscription on the 7th and 8th, it plans to be listed on the KOSDAQ market within August. Korea Investment & Securities is the lead underwriter.

Established in 2014, Nextbiomedical leads the innovative therapeutic agent market by developing the world's first ▲endoscopic hemostatic agent ‘NexpowderTM’ ▲vascular embolic microparticles ‘NexsphereTM’, and musculoskeletal pain embolic therapeutic agent ‘Nexsphere-FTM’.

◆Jeonjin Construction Robot= The desired public offering price per share is KRW 13,800 to KRW 15,700, with a total expected offering amount of approximately KRW 42.5 billion to KRW 48.3 billion. Demand forecasting will be conducted until the 5th, followed by general subscription on the 8th and 9th, aiming for listing within August. Mirae Asset Securities is the lead underwriter.

Jeonjin Construction Robot is a subsidiary of Motrex, a KOSDAQ-listed company, and is the largest concrete pump car (CPC) manufacturer in Korea. A concrete pump car (CPC) is essential equipment at construction sites that pumps cement or concrete to enable high-rise and long-distance pouring work.

◆K3I= The desired public offering price band is KRW 12,500 to KRW 15,500. Demand forecasting will be conducted until the 5th to finalize the public offering price, and subscription will be held on the 8th and 9th before listing on the KOSDAQ market. Hana Securities is the lead underwriter.

Founded in 2000, K3I is the only domestic company that developed the ‘XR Middleware Solution (Universe XR Framework)’. The ‘XR Middleware Solution’ is an open software essential for developing and running XR content, and it is a core technology first developed domestically by K3I in 2015.

◆TDS Pharm= The public offering price per share is KRW 9,500 to KRW 10,700. Demand forecasting targeting institutional investors will be conducted until the 6th to finalize the final public offering price, and general subscription will be held from the 9th to the 12th. Korea Investment & Securities is the lead underwriter.

Established in 2002, TDS Pharm operates mainly in the development and manufacturing of transdermal drug delivery systems (TDDS), a high-growth sector within drug delivery systems (DDS). TDDS is a drug delivery system that delivers drugs through the skin at a controlled rate.